Clinical

Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.

Clinical updates for August 2020 featured in Evidence-Based Oncology.

A new study of patients with rheumatoid arthritis (RA) in Korea has shown that only about half of patients with RA who attained clinical remission were also in imaging remission.

The thalamus is among the first brain areas to atrophy in multiple sclerosis (MS); this study wanted to know if measuring this loss can predict future disability.

Patients with connective tissue diseases are at greater risk for severe coronavirus disease 2019 (COVID-19) than patients with chronic inflammatory arthritis.

The risk of orthopedic surgery has declined for patients with rheumatoid arthritis (RA) over the course of decades, but the same trend has not occurred for patients with psoriatic arthritis.

An adolescent boy went to his physician with a headache that got worse with physical activity. Testing showed autoimmune myelofibrosis.

A significant proportion of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) experience bleeding when taking ibrutinib—a recent study probes why.

High-quality research is needed to generate evidence to back neurofeedback for pain management, a recent review says.

A study in Annals of Internal Medicine shows severe obesity presents a greater risk of death from COVID-19 than related factors such as diabetes or hypertension.

In individuals with type 1 diabetes (T1D), bacterial infections are associated with an increased risk of coronary heart disease, according to a study published in the Journal of Internal Medicine.

It is the first such approval for a diagnostic that combines next-generation sequencing and liquid biopsy in one test.

A real-world study showed that ruxolitinib is a safe treatment for patients with myelofibrosis.

AJMC interviews Jill A. Fisher, PhD, author of a new book, Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals. Her research took her inside clinical testing sites for phase 1 drug studies.

Among patients with Parkinson disease aged 60 years and younger with early motor complications, deep brain stimulation was found to provide significant improvements in social, occupational, and psychosocial function.

A new commentary outlines UK guidance about evidence regarding the appropriateness of blood component irradiation for preventing transfusion-associated graft-versus-host disease (TA-GVHD).

New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.

A recent meta-analysis looked at noninvasive vagus nerve stimulation (nVNS), a nonpharmacologic method of acute pain relief for headaches.

The FDA has approved risdiplam, the first at-home, oral treatment for spinal muscular atrophy.

In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.

Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.

A new analysis offers insights into how ozanimod works in patients with relapsing multiple sclerosis, as well as the impact of higher dosage.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).

Patricia Salber, MD, MBA, of The Doctor Weighs In, and Sandeep “Bobby” Reddy, MD, an oncologist at Harbor-UCLA Medical Center and chief medical officer of NantHealth, discuss the clinical care of patients with cancer in the age of COVID-19.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

Transferring from pediatric to adult care can result in difficulties for patients with childhood-onset systemic lupus erythematosus.